Roy D. Baynes, serving as a director at Travere Therapeutics, Inc. (NASDAQ: TVTX), executed a transaction involving the sale of 4,500 shares of the company's common stock on June 12, 2026. The transaction was completed at a price of $50.00 per share, resulting in a total value of $225,000. This activity took place while the stock was trading near its 52-week high of $54.38, with the share price recorded at $53.38 following the transaction. The sale was facilitated through a pre-arranged 10b5-1 trading plan adopted on November 17, 2025. This mechanism is designed to establish a predetermined schedule for insider transactions to avoid potential accusations of insider trading.
Concurrently, Mr. Baynes exercised stock options to acquire an additional 4,500 shares at an exercise price of $21.38 per share, totaling $96,210. These options were fully vested and carry an expiration date of May 11, 2032. Following these movements, Mr. Baynes maintains a direct holding of 41,500 shares of Travere Therapeutics common stock. The transaction occurs alongside significant corporate developments, including the presentation of long-term data from the Phase 3 DUPLEX Study on FILSPARI for focal segmental glomerulosclerosis, a leadership change involving the retirement of Chief Research Officer William Rote, and a new collaboration agreement with Everest Medicines for civorebrutinib. H.C. Wainwright has also raised its price target for the stock to $67, maintaining a Buy rating.
The sale of shares by Mr. Baynes highlights the ongoing executive activity within Travere Therapeutics. The use of a 10b5-1 plan indicates a structured approach to managing insider transactions, which is a common practice for executives and directors to ensure compliance with securities regulations. The exercise of stock options further demonstrates the alignment of executive interests with the company's long-term performance, as the options were fully vested and carry a significant expiration date.
Corporate developments at Travere Therapeutics include the presentation of long-term data from the Phase 3 DUPLEX Study on FILSPARI for focal segmental glomerulosclerosis. The data showed sustained reductions in proteinuria over approximately five years, providing insight into the long-term efficacy of the treatment. Additionally, the company announced a leadership change, with Chief Research Officer William Rote set to retire in February 2027 after a decade with the company. Jula Inrig, currently the Chief Medical Officer, will take over Rote's responsibilities and expand her role as Executive Vice President, Head of Research and Development.
Furthermore, Travere Therapeutics has entered into a license and collaboration agreement with Everest Medicines, granting them exclusive rights to develop and commercialize civorebrutinib outside China and certain Asian regions. This agreement includes the right to sublicense certain patents and know-how related to the BTK inhibitor. In the realm of financial analysis, H.C. Wainwright has raised its price target for Travere Therapeutics to $67, maintaining a Buy rating on the shares. The firm highlighted potential upside from the inclusion of additional indications in its valuation.
These developments reflect ongoing strategic and operational advancements at Travere Therapeutics. The combination of executive transactions, clinical data presentations, leadership transitions, and new collaborations underscores the dynamic nature of the company's operations. The stock's performance, trading near its 52-week high, suggests market interest in these developments. The financial metrics and analyst ratings provide additional context for investors evaluating the company's prospects.